“Center for Clinical Cancer Genetics: 2018 Program Update” |
10/08/2018 - 12:00pm to 1:00pm |
“Targeting the Beta-Catenin Pathway to Overcome Immunotherapy Resistance of Beta-catenin Expressing Tumors” and “Diving into the Deep End: Minimal Residual Disease in Multiple Myeloma” |
10/15/2018 - 12:00pm to 1:00pm |
“The Role of Bacterial Driven Inflammation in TET2 Mutated Clonal Hematopoiesis: Update and Future Directions” and “Clinical and Molecular Correlates of Immunotherapy Response and Resistance” |
10/22/2018 - 12:00pm to 1:00pm |
“The Impact of PTEN-Deficiency on Immunotherapy Response: Current Understanding and Future Directions” and “A Spotlight on the Hematologic Toxicities of Immune Checkpoint Inhibitors” |
10/29/2018 - 12:00pm to 1:00pm |
“Utilizing Pharmacogenomics to Risk-Mitigate Chemotherapy-Related Toxicities” and “Brewing SolutionsTo the “Cold” Tumor Microenvironment: A Role for the A2A Adenosine Receptor?” |
11/05/2018 - 12:00pm to 1:00pm |
“Targeting Cellular Metabolism Through Modulation of BACH1 in Triple-Negative Breast Cancer” |
11/12/2018 - 12:00pm to 1:00pm |
“Healthcare Resource Allocation: Ethically Addressing U.S. Medication & Personnel Scarcity” |
11/19/2018 - 12:00pm to 1:00pm |
“The HNC Program: What it takes to Change the Standard of Care” |
11/26/2018 - 12:00pm to 1:00pm |
“Identifying Oncogenic Pathways that Mediate Evasion from Anti-Tumor Immunity” |
12/10/2018 - 12:00pm to 1:00pm |
“Putting the Brakes on the CAR T: Management of CAR T Toxicities” and “Factors Impacting Outcomes in Adolescent & Young Adults (AYA) with Hematologic Malignancies” |
12/17/2018 - 12:00pm to 1:00pm |